http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20120104154-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e78e9f4d75167a3feec127909f18994 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-01001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-82 |
| filingDate | 2010-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96c827e149efaa013405f42e28f72e18 |
| publicationDate | 2012-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20120104154-A |
| titleOfInvention | PIized L-asparaginase |
| abstract | Conjugates of polyethylene glycol and proteins having substantially L-asparagine aminohydrolase activity are disclosed. In particular, polyethylene glycol has a molecular weight of about 5000 Da or less and the protein is L-asparaginase obtained from Erwinia . The conjugates of the present invention exhibit excellent properties such as maintenance of high levels of in vitro activity and unexpected increase in half-life in vivo. Also disclosed is the use of the conjugates in the preparation and treatment of the conjugates. In particular, methods of using the conjugates in the treatment of cancer, in particular acute lymphoblastic leukemia (ALL), are disclosed. More specifically, methods of using the conjugates as secondary therapeutics for patients with developed hypersensitivity or disease relapse after treatment with other L-asparaginase formulations are disclosed. |
| priorityDate | 2009-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 525.